Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin: 2009-2025

Historic Gross Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -7.89%.

  • China Pharma Holdings' Gross Margin rose 3935.00% to -7.89% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.94%, marking a year-over-year increase of 2340.00%. This contributed to the annual value of -43.84% for FY2024, which is 3983.00% down from last year.
  • As of Q3 2025, China Pharma Holdings' Gross Margin stood at -7.89%, which was up 7.00% from -8.48% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Gross Margin registered a high of 11.56% during Q1 2021, and its lowest value of -109.78% during Q2 2024.
  • Moreover, its 3-year median value for Gross Margin was -12.93% (2023), whereas its average is -21.96%.
  • As far as peak fluctuations go, China Pharma Holdings' Gross Margin slumped by 9,642bps in 2024, and later soared by 10,130bps in 2025.
  • Over the past 5 years, China Pharma Holdings' Gross Margin (Quarterly) stood at 10.45% in 2021, then slumped by 899bps to 1.46% in 2022, then slumped by 514bps to -3.68% in 2023, then plummeted by 1,048bps to -14.16% in 2024, then skyrocketed by 3,935bps to -7.89% in 2025.
  • Its Gross Margin stands at -7.89% for Q3 2025, versus -8.48% for Q2 2025 and -11.97% for Q1 2025.